Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1997 1
1998 6
1999 6
2000 6
2001 6
2002 7
2003 5
2004 9
2005 7
2006 10
2007 9
2008 30
2009 23
2010 13
2011 10
2012 10
2013 8
2014 15
2015 6
2016 6
2017 6
2018 5
2019 4
2020 3
2021 3
2022 6
2023 9
2024 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Peters S, et al. Among authors: mitry e. N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6. N Engl J Med. 2017. PMID: 28586279 Free article. Clinical Trial.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial.
Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, Mitry E, Biagi JJ, Evesque L, Artru P, Lecomte T, Assenat E, Bauguion L, Ychou M, Bouché O, Monard L, Lambert A, Hammel P; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Conroy T, et al. Among authors: mitry e. JAMA Oncol. 2022 Nov 1;8(11):1571-1578. doi: 10.1001/jamaoncol.2022.3829. JAMA Oncol. 2022. PMID: 36048453 Free PMC article. Clinical Trial.
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD; ENETS consensus conference participants. Caplin ME, et al. Ann Oncol. 2015 Aug;26(8):1604-20. doi: 10.1093/annonc/mdv041. Epub 2015 Feb 2. Ann Oncol. 2015. PMID: 25646366 Free article. Review.
Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial.
Nicolle R, Bachet JB, Harlé A, Iovanna J, Hammel P, Rebours V, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lopez A, Biagi J, François E, Artru P, Lambert A, Renouf DJ, Monard L, Mauduit M, Dusetti N, Conroy T, Cros J. Nicolle R, et al. Among authors: mitry e. J Clin Oncol. 2024 Mar 20;42(9):1067-1076. doi: 10.1200/JCO.22.02668. Epub 2023 Nov 14. J Clin Oncol. 2024. PMID: 37963313 Free PMC article.
Gastrinoma (duodenal and pancreatic).
Jensen RT, Niederle B, Mitry E, Ramage JK, Steinmuller T, Lewington V, Scarpa A, Sundin A, Perren A, Gross D, O'Connor JM, Pauwels S, Kloppel G; Frascati Consensus Conference; European Neuroendocrine Tumor Society. Jensen RT, et al. Among authors: mitry e. Neuroendocrinology. 2006;84(3):173-82. doi: 10.1159/000098009. Epub 2007 Feb 20. Neuroendocrinology. 2006. PMID: 17312377 Free article. No abstract available.
Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma.
Fraunhoffer N, Hammel P, Conroy T, Nicolle R, Bachet JB, Harlé A, Rebours V, Turpin A, Ben Abdelghani M, Mitry E, Biagi J, Chanez B, Bigonnet M, Lopez A, Evesque L, Lecomte T, Assenat E, Bouché O, Renouf DJ, Lambert A, Monard L, Mauduit M, Cros J, Iovanna J, Dusetti N. Fraunhoffer N, et al. Among authors: mitry e. Ann Oncol. 2024 Sep;35(9):780-791. doi: 10.1016/j.annonc.2024.06.010. Epub 2024 Jun 19. Ann Oncol. 2024. PMID: 38906254 Free article.
Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Boige V, Blons H, François E, Ben Abdelghani M, Phelip JM, Le Brun-Ly V, Mineur L, Galais MP, Villing AL, Hautefeuille V, Miglianico L, De La Fouchardière C, Genet D, Levasseur N, Levaché CB, Penel N, Mitry E, Jacquot S, Aparicio T, Brument E, Gourgou S, Castan F, Bouché O. Boige V, et al. Among authors: mitry e. JAMA Netw Open. 2023 Sep 5;6(9):e2333533. doi: 10.1001/jamanetworkopen.2023.33533. JAMA Netw Open. 2023. PMID: 37721754 Free PMC article. Clinical Trial.
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study.
Van Laethem JL, Borbath I, Prenen H, Geboes KP, Lambert A, Mitry E, Cassier PA, Blanc JF, Pilla L, Batlle JF, Garrote MR, Pazo-Cid RA, Gallego I, Smith KE, Ellmark P, Pico de Coaña Y, Ambarkhane SV, Macarulla T. Van Laethem JL, et al. Among authors: mitry e. Lancet Oncol. 2024 Jul;25(7):853-864. doi: 10.1016/S1470-2045(24)00263-8. Epub 2024 Jun 1. Lancet Oncol. 2024. PMID: 38834087 Clinical Trial.
212 results